Compare PGEN & AEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PGEN | AEF |
|---|---|---|
| Founded | 1998 | 1989 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 315.9M |
| IPO Year | 2013 | N/A |
| Metric | PGEN | AEF |
|---|---|---|
| Price | $4.08 | $7.93 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $8.33 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 170.8K |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 7.13% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 0.57 |
| Revenue | ★ $230,981,000.00 | N/A |
| Revenue This Year | $1,115.92 | N/A |
| Revenue Next Year | $81.04 | N/A |
| P/E Ratio | ★ N/A | $13.16 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.23 | $4.49 |
| 52 Week High | $5.47 | $8.93 |
| Indicator | PGEN | AEF |
|---|---|---|
| Relative Strength Index (RSI) | 57.08 | 58.18 |
| Support Level | $4.02 | $7.52 |
| Resistance Level | $4.44 | $8.09 |
| Average True Range (ATR) | 0.32 | 0.29 |
| MACD | 0.12 | 0.07 |
| Stochastic Oscillator | 80.38 | 45.83 |
Precigen Inc is a commercial-stage biopharmaceutical company focused on developing precision medicines to improve the lives of patients, targeting immuno-oncology, autoimmune disorders, and infectious diseases using its proprietary and complementary technology platforms. These platforms support the development of gene programs, delivery through viral, non-viral, and microbe-based approaches, and control of gene expression for safety and efficacy. Its key platforms include AdenoVerse immunotherapy and UltraCAR-T, supported by the UltraPorator device for rapid and cost-effective manufacturing. Its clinical pipeline includes PRGN-2009, PRGN-3005, PRGN-3006, and PRGN-3007. Its reportable segments are Biopharmaceuticals and Exemplar.
ABERDEEN EMERGING MARKETS EQUITY INCOME FUND, INC. is a closed-end investment company. The Fund's investment objective is to seek to provide both current income and long-term capital appreciation. The Fund invests in a range of sectors, including financials, consumer staples, utilities, consumer discretionary, materials, energy, information technology, private equity, communication services, healthcare, real estate, and industrials.